Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC)

Sponsor
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Study ID
NCT06793813
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Non-Squamous
  • Stage IVB Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • cadonilimab，bevacizumab，docetaxel — DRUG
    Patients receive Cadonilimab IV over 90 minutes on day 1. Patients also receive bevacizumab 7.5mg/kg IV on day 1 and docetaxel 60-75 mg/m2 IV over 60 minutes on day 1. Cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Study Details

This phase II trial studies how well cadonilimab combined with Bevacizumab and docetaxel work in treating patients with non-squamous and stage IV non-small cell lung cancer. Cadonilimab, a PD-1/CTLA-4 bispecific antibody, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Bevacizumab can regulate tumor microenvironment. Docetaxel was used in standard of care chemotherapy for non-small cell lung cancer, work to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving cadonilimab, bevacizumab and docetaxel together may work better in treating patients with non-squamous non-small lung cancer compared to standard of care.

Key Dates

First listed
Jan 27, 2025
Start date
Jan 23, 2024
Status verified
Jan 2024
Primary completion
Dec 30, 2025
Completion
Dec 30, 2026

Study Design

Enrollment
44 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Arm A (cadonilimab，bevacizumab，docetaxel )

Primary Outcome Measure

6-month progression-free survival [ Time Frame: up to 6 months ]

Central Contacts